Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor

Vascular endothelial growth factor receptor (VEGFR) inhibitors are approved for the treatment of several tumor types; however, some tumors show intrinsic resistance to VEGFR inhibitors, and some patients develop acquired resistance to these inhibitors. Therefore, a strategy to overcome VEGFR inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakagawa, Takayuki, Matsushima, Tomohiro, Kawano, Satoshi, Nakazawa, Youya, Kato, Yu, Adachi, Yusuke, Abe, Takanori, Semba, Taro, Yokoi, Akira, Matsui, Junji, Tsuruoka, Akihiko, Funahashi, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317894/
https://www.ncbi.nlm.nih.gov/pubmed/24689876
http://dx.doi.org/10.1111/cas.12409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317894/
https://www.ncbi.nlm.nih.gov/pubmed/24689876
http://dx.doi.org/10.1111/cas.12409

Ejemplares similares